| Sophia Genetics–Generation Investment Management: investment, 201901 financing round Series E totalling $77m incl new + lead investor Generation |
2019-01-04 |
| Sophia Genetics–SEVERAL: investment, 201901 financing round Series E $77m incl new + lead investor Generation Investment Management LLP |
2019-01-04 |
| Atriva Therapeutics–High-Tech Gründerfonds: investment, 201901 financing round Series A first closing led by Meneldor + HTGF |
2019-01-03 |
| Atriva Therapeutics–MC Services: public relations, 201901 service existent by MC Services |
2019-01-03 |
| Atriva Therapeutics–Meneldor: investment, 201901 financing round Series A first closing led by Meneldor + HTGF |
2019-01-03 |
| Atriva Therapeutics–SEVERAL: investment, 201901 financing round Series A first closing led by Meneldor + HTGF |
2019-01-03 |
| Takeda–Rentschler: biologics contract manufacturing, 201901– supply service continued production for Shire in acquired manufacturing site in Milford |
2019-01-03 |
| CARB-X–Germany (govt): grant, 201901–202212 BMBF commits €40m over 4 years |
2019-01-01 |
| Curetis–Vienna (govt): grant, 201901–202106 co-funding of developm project of Ares Genetics for AMR assay by Vienna Business Agency |
2019-01-01 |
| Delfi Diagnostics–Allianz: investment, 2019 seed financing round totalling $5.5m incl co-investor AV8 Ventures |
2019-01-01 |
| Delfi Diagnostics–SEVERAL: investment, 2019 seed financing round $5.5m led by Menlo Ventures |
2019-01-01 |
| Marinomed–EU (govt): credit, 20901–2027 up to €15m EIB credit 2019–2022 repayable 2024–2027 |
2019-01-01 |
| Medicomp–KLIFO: investment, 2019 acquisition of Medicomp GmbH by KLIFO A/S |
2019-01-01 |
| Blink Biomedical–Valneva: investment, 201812 existing shareholding of 43.3% by Valneva consolidated via equity method |
2018-12-31 |
| Murdoch Univ–Bruker: mass spectrometer, 2018–201909 supply FIA-MRMS system |
2018-12-31 |
| Murdoch Univ–Bruker: mass spectrometer, 2018–201909 supply twelve impact-II UHR-QTOF LC-MS/MS systems |
2018-12-31 |
| Murdoch Univ–Bruker: mass spectrometer, 2018–201909 supply two timsTOF Pro LC/CCS/MS/MS systems |
2018-12-31 |
| Murdoch Univ–Bruker: NMR spectrometer, 2018–201909 supply seven Avance IVDr 600 NMR systems |
2018-12-31 |
| Qiagen–Formulatrix: digital PCR technology, 201812– acquisition of all dPCR assets of Formulatrix for $125m upfront cash + $135m milestones |
2018-12-31 |
| Harpoon Therapeutics–SEVERAL: investment, 201812–201902 IPO $76m at $14/share |
2018-12-27 |
| AC Immune–WuXi Pharmatech: biologics contract manfucturing, 201812– collab strategic alliance biologics CDMO with WuXi Biologics |
2018-12-19 |
| Amgen–Molecular Partners: cancer immunotherapy, 201812– collab $50m upfront + $497m milestones + royalties ww excl developm + commerc rights to MP0310 |
2018-12-18 |
| Novartis–Curetis: antibiotics research, 201812– collab Sandoz to use Ares Genetics’ antibiotic resistance database ARESdb |
2018-12-18 |
| Versameb–SEVERAL: investment, 201812 closing of seed B financing round brining total capital raised to date to CHF5.3m |
2018-12-18 |
| Shire–Rentschler: investment, 201812–201901 acquisition €na of Shire’s manufacturing facility in Milford, MA by Rentschler Biopharma SE |
2018-12-17 |
| Noxxon–MC Services: public relations, 201812 service existent by MC Services |
2018-12-14 |
| Noxxon–Trophic Communications: public relations, 201812 service existent by Trophic Communications |
2018-12-14 |
| Lonza–ERS Genomics: CRISPR technology, 201812– license €na for bioproduction products + services + iPSC research to Lonza Pharma & Biotech |
2018-12-13 |
| AC Immune–Lilly: credit, 201812 convertible note $50m in connection with license + collab agreement |
2018-12-12 |
| Imprint Analytics–SGS: credit, 201812– convertible loan as part of strategic partnership |
2018-12-12 |
| Lilly–AC Immune: tau aggregation inhibitors, 201812– collab + license agreem CHF80m upfront + CHF1.76b milestones + royalties |
2018-12-12 |
| SGS–Imprint Analytics: food analysis, 201812– collab strategic partnership isotope analysis for proof of origin + authenticity food testing |
2018-12-12 |
| DenovoMatrix–High-Tech Gründerfonds: investment, 201812 seed financing round from HTGF + TGFS |
2018-12-11 |
| DenovoMatrix–Saxony (govt): investment, 201812 seed financing round from HTGF + TGFS |
2018-12-11 |
| DenovoMatrix–SEVERAL: investment, 201812 seed financing round from HTGF + TGFS |
2018-12-11 |
| genOway–Merck (DE): CRISPR technology, 202001– collab strategic alliance extention incl adding non-excl license for all non-rodent animal cell models |
2018-12-10 |
| Novartis–Intellia Therapeutics: CRISPR technology, 201812–201912 collab + license agreem expansion incl $10m upfront payment + milestones + royalties |
2018-12-06 |
| Merck (DE)–V7: AI software, 201812– collab on software that scientists can use to tag images for future use in training AI software |
2018-12-05 |
| Dispendix–Cellink: investment, 201812 acquisition €5m of Dispendix GmbH by Cellink AB |
2018-12-01 |
| Resistell–SEVERAL: investment, 201812 seed financing round CHF850k |
2018-12-01 |
| Rheostat Therapeutics–SEVERAL: investment, 201811 financing round Series A $23m co-led by MRL Ventures + AbbVie Ventures |
2018-11-26 |
| AbbVie–Mission Therapeutics: DUB inhibitors, 201811– collab RnD + license option €na for Alzheimer’s + Parkinson’s diseases |
2018-11-15 |
| Cadent Therapeutics–Access Industries: investment, 201811 financing round Series B totalling $40m incl co-investor Access Industries |
2018-11-15 |
| Cadent Therapeutics–Atlas Venture: investment, 201811 financing round Series B totalling $40m incl co-lead investor Atlas Venture |
2018-11-15 |
| Cadent Therapeutics–Clal Industries: investment, 201811 financing round Series B totalling $40m incl co-investor Clal Biotechnology Industries |
2018-11-15 |
| Cadent Therapeutics–Cowen: investment, 201811 financing round Series B totalling $40m incl co-lead investor Cowen Healthcare Investments |
2018-11-15 |
| Cadent Therapeutics–Novartis: investment, 201811 financing round Series B totalling $40m incl co-investor Novartis Institutes for Biomedical Research |
2018-11-15 |
| Cadent Therapeutics–Qiming: investment, 201811 financing round Series B totalling $40m incl co-investor Qiming Venture Partners |
2018-11-15 |
| Cadent Therapeutics–SEVERAL: investment, 201811 financing round Series B $40m co-led by Cowen Healthcare Investments + Atlas Venture |
2018-11-15 |
| Virion Biotherapeutics–Trophic Communications: public relations, 201811 service existent by Trophic |
2018-11-14 |
| Immunic–Daiichi Sankyo: IMU-856, 201811– license option agreem ww excl to in-license + develop IMU-856 program for IBD |
2018-11-05 |
| Psyros Diagnostics–Novartis: point-of-care diagnostics, 201811 acquisition IP + equipment related to Niji point-of-care dx platform from Novartis |
2018-11-01 |
| Q-Bioanalytic–Eurofins: investment, 201811 acquisition by Eurofins |
2018-11-01 |
| Rheostat Therapeutics–SV Health Investors: investment, <201811 Rheostat incubated + seeded by SV Health Investors + Dementia Discovery Fund |
2018-11-01 |
| Galecto–BPCE: investment, 201810 financing round Series C totalling €79m incl new + co-investor Seventure Partners |
2018-10-26 |
| XtalPi–SEVERAL: investment, 201810 financing round Series B-1 extension $46m led by China Life Healthcare Fund |
2018-10-24 |
| XtalPi–Swiss Investment Group: investment, 201810 financing round Series B-1 extension totalling $46m incl co-investor SIG |
2018-10-24 |
| Genome Biologics (DE)–EU (govt): grant, 201810 Horizon 2020 Phase 2 Grant €2.42m |
2018-10-22 |
| Kumovis–Ffilipa Venture Capital: investment, 201810 seed financing round totalling 7-digit € incl family office |
2018-10-17 |
| Kumovis–High-Tech Gründerfonds: investment, 201810 seed financing round totalling 7-digit € incl investor HTGF |
2018-10-17 |
| Kumovis–SEVERAL: investment, 201810 seed financing round 7-digit € from HTGF + Ffilipa Venture Capital |
2018-10-17 |
| Atai Life Sciences–SEVERAL: investment, 201810 1st financing round €21.2m from private investors |
2018-10-01 |
| Neuron23–SEVERAL: investment, 201810c financing round Series A $33.5m from Westlake Village BioPartners + Kleiner Perkins |
2018-10-01 |
| Novaliq–Hopp Group: investment, 201810 financing round €44.9m from Dievini Hopp BioTech Holding GmbH |
2018-10-01 |
| Bayer–Inova Software: business development software, 201809 supply existent Bayer is user of Inova Partnering Platform |
2018-09-27 |
| Lilly–Inova Software: business development software, 201809 supply existent Lilly is user of Inova Partnering Platform |
2018-09-27 |
| Novartis–Inova Software: business development software, 201809 supply existent Novartis is user of Inova Partnering Platform |
2018-09-27 |
| Roche–Inova Software: business development software, 201809 supply existent Roche is user of Inova Partnering Platform |
2018-09-27 |
| Tolremo Therapeutics–Altos Venture: investment, 201809 financing round Series A totalling CHF9m incl new + co-investor Altos Venture |
2018-09-24 |
| Tolremo Therapeutics–BioMedPartners: investment, 201809 financing round Series A totalling CHF9m incl new + lead investor BioMedPartners |
2018-09-24 |
| Tolremo Therapeutics–Redalpine: investment, 201809 financing round Series A totalling CHF9m incl new + co-investor Redalpine |
2018-09-24 |
| Tolremo Therapeutics–Zürcher Kantonalbank: investment, 201809 financing round Series A totalling CHF9m incl exisintg + co-investor ZKB |
2018-09-24 |
| Luciole Medical–Trophic Communications: public relations, 201809 service existent by Trophic Communications |
2018-09-17 |
| NeuMoDx–Qiagen: investment, 201809 existent Qiagen owns 19.9% of NeuMoDx |
2018-09-17 |
| NeuMoDx–Qiagen: investment, 201809– option to acquire remaining 80.1% of NeuMoDx for $234m |
2018-09-17 |
| Qiagen–NeuMoDx: molecular diagnostics, 201809– collab distribution outside US by Qiagen + implementation of Qiagen reagents on NeuMoDex PRC systems |
2018-09-17 |
| Coda Biotherapeutics–SEVERAL: investment, 201809 financing round Series A $19m co-led by MPM Capital + Versant Ventures |
2018-09-12 |
| Twentyeight-Seven–Astellas: investment, 201809 financing round Series A totalling $65m incl co-investor Astellas Venture Management |
2018-09-06 |
| Twentyeight-Seven–JnJ: investment, 201809 financing round Series A totalling $65m incl co-investor JnJ Innovation JJDC Inc |
2018-09-06 |
| Twentyeight-Seven–Longwood Fund: investment, 201809 financing round Series A totalling $65m incl co-investor Longwood Fund |
2018-09-06 |
| Twentyeight-Seven–MPM Capital: investment, 201809 financing round Series A totalling $65m incl founding + co-lead investor MPM Capital |
2018-09-06 |
| Twentyeight-Seven–Novartis: investment, 201809 financing round Series A totalling $65m incl co-lead investor NVF |
2018-09-06 |
| Twentyeight-Seven–SEVERAL: investment, 201809 financing round Series A $65m co-led by founding investor MPM Capital + NVF |
2018-09-06 |
| Twentyeight-Seven–Temasek: investment, 201809 financing round Series A totalling $65m incl co-investor Vertex Ventures HC |
2018-09-06 |
| Creoptix–Waters: investment, 201809 investment by new investor Waters Corp |
2018-09-05 |
| Proteomedix–Altos Venture: investment, 201808 financing round totalling CHF5.2m incl exising + lead investor Altos Venture |
2018-08-27 |
| Proteomedix–SEVERAL: investment, 201808 financing round CHF5.2m from exising investors led by Altos Venture + incl ZKB |
2018-08-27 |
| Proteomedix–Zürcher Kantonalbank: investment, 201808 financing round totalling CHF5.2m incl exising + co-investor ZKB |
2018-08-27 |
| Bayer–Leo Pharma: investment, 201807–201907 acquisition of global prescription dermatology business of Bayer |
2018-07-31 |
| Daiichi Sankyo–Glycotope: antibody-drug conjugates, 201807– license ww excl €na to develop ADC using Daiichi ADC technology with gatipotuzumab |
2018-07-30 |
| S-Biomedic–JnJ: investment, 201807 financing round Series A 1st closing totalling €2m incl co-investor JnJ Innovation JJDC |
2018-07-18 |
| S-Biomedic–Verve Capital Partners: investment, 201807 financing round Series A 1st closing totalling €2m incl co-investor investiere.ch |
2018-07-18 |
| Mosa Meat–Bell Food: investment, 201807 financing round Series A totalling €7.5m incl co-lead investor Bell Food Group |
2018-07-17 |
| Mosa Meat–Glass Wall Syndicate: investment, 201807 financing round Series A totalling €7.5m incl co-investor Glass Wall Syndicate |
2018-07-17 |
| Mosa Meat–Merck (DE): investment, 201807 financing round Series A totalling €7.5m incl co-lead investor M Ventures |
2018-07-17 |
| Mosa Meat–SEVERAL: investment, 201807 financing round Series A €7.5m co-led by M Ventures + Bell Food Group |
2018-07-17 |
| Inveox–SEVERAL: investment, 201807c 2nd financing round €5m from four founding business angels |
2018-07-01 |
| Arvinas–Bayer: investment, 201806 founding agricultural 50/50 joint venture w $55m committed funding from Bayer + techn + IP from Arvinas |
2018-06-04 |
| Bayer–Arvinas: PROTAC technology, 201806– collab agricultural 50/50 joint venture w $55m committed funding from Bayer + techn + IP from Arvinas |
2018-06-04 |
| Tricares–Andera Partners: investment, 201806 financing round Series B totalling €22m incl new + co-lead investor Andera Partners |
2018-06-04 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 ... 40 41 42 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
